Medicine
Yuviwel kit
Yuviwel kit is a prescription medicine containing Navepegritide, marketed by Ascendis Pharma Endocrinology, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store YUVIWEL refrigerated between 2°C to 8°C (36°F to 46°F). Do not freeze…
Key facts
- Active ingredient (INN)
- Navepegritide
- Brand
- Yuviwel
- Dosage form
- Kit
- Packs
- 4 boxes
- Marketing authorisation holder
- Ascendis Pharma Endocrinology
- Manufacturer
- Ascendis Pharma Endocrinology
- Origin register
- US FDA, United States
- Storage
- Store YUVIWEL refrigerated between 2°C to 8°C (36°F to 46°F). Do not freeze. YUVIWEL can also be stored at room temperature up to 30°C (86°F) for up to 6 months and can be returned to refrigeration within the 6 months. Do not use YUVIWEL beyond the expiration date or 6 months after the date it was first removed from refrigeration (whichever is earlier).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 27 February 2026
- Identifiers
- RxCUI 2739524, 2739529, 2739531 +3DailyMed set ID e01c1197-338f-414c-b804-808e129ebc8cNDC 73362-203, 73362-202, 73362-201Application NDA219164
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 box in 1 carton / 1 kit in 1 box * 1 injection, powder, lyophilized, for solution in 1 vial, glass * 1 solution in 1 syringe, glass | 73362-201-01 | Ascendis Pharma Endocrinology | 27 February 2026 |
| 4 box in 1 carton / 1 kit in 1 box * 1 injection, powder, lyophilized, for solution in 1 vial, glass * 1 solution in 1 syringe, glass | 73362-202-01 | Ascendis Pharma Endocrinology | 27 February 2026 |
| 4 box in 1 carton / 1 kit in 1 box * 1 injection, powder, lyophilized, for solution in 1 vial, glass * 1 solution in 1 syringe, glass | 73362-203-01 | Ascendis Pharma Endocrinology | 27 February 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 27 February 2026 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Navepegritide is a prescription medicine indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. It is available as kits. MedsAcross supplies Navepegritide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about NavepegritideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Yuviwel prescribing information (Ascendis Pharma Endocrinology) · U.S. National Library of Medicine, DailyMed
Need Yuviwel kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.